Open‐label follow‐on study evaluating the efficacy, safety, and quality of life with extended daily oral immunotherapy in children with peanut allergy

BACKGROUND: The benefit of daily administration of Peanut (Arachis hypogaea) Allergen Powder‐dnfp (PTAH)—formerly AR101—has been established in clinical trials, but limited data past the first year of treatment are available. This longitudinal analysis aimed to explore the impact of continued PTAH t...

Descripción completa

Detalles Bibliográficos
Autores principales: Fernandez‐Rivas, Montserrat, Vereda, Andrea, Vickery, Brian P., Sharma, Vibha, Nilsson, Caroline, Muraro, Antonella, Hourihane, Jonathan O'B., DunnGalvin, Audrey, du Toit, George, Blumchen, Katharina, Beyer, Kirsten, Smith, Alex, Ryan, Robert, Adelman, Daniel C., Jones, Stacie M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293305/
https://www.ncbi.nlm.nih.gov/pubmed/34320250
http://dx.doi.org/10.1111/all.15027

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293305/
https://www.ncbi.nlm.nih.gov/pubmed/34320250
http://dx.doi.org/10.1111/all.15027

Ejemplares similares